Nabriva Therapeutics AG (NBRV) Releases Quarterly Earnings Results, Beats Expectations By $5.29 EPS
Nabriva Therapeutics AG (NASDAQ:NBRV) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29, MarketWatch Earnings reports. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) remained flat at $10.50 on Tuesday. 9,232 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $10.26 and a 200 day moving average price of $10.28. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75. The firm’s market capitalization is $28.57 million.
In other news, Director George Harrison Talbot sold 325 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $100.56, for a total value of $32,682.00. Following the sale, the director now directly owns 3,854 shares of the company’s stock, valued at approximately $387,558.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Hbm Healthcare Investments (Ca sold 6,585 shares of the company’s stock in a transaction dated Friday, July 28th. The stock was sold at an average price of $10.51, for a total transaction of $69,208.35. Following the completion of the sale, the insider now directly owns 2,391,177 shares in the company, valued at $25,131,270.27. The disclosure for this sale can be found here. Insiders sold a total of 205,115 shares of company stock worth $2,252,057 over the last ninety days.
A number of equities research analysts have commented on NBRV shares. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Saturday, May 27th. Cantor Fitzgerald started coverage on shares of Nabriva Therapeutics AG in a report on Thursday, June 22nd. They issued a “buy” rating and a $16.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. Finally, ValuEngine cut shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Nabriva Therapeutics AG has an average rating of “Buy” and a consensus price target of $15.43.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.